<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Tuberomammillary Nucleus Histamine Neurons</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Histidine Decarboxylase (HDC)</td>
<td>Converts L-histidine to histamine</td>
</tr>
<tr>
<td class="label">Vesicular Monoamine Transporter 2 (VMAT2)</td>
<td>Packages histamine into vesicles</td>
</tr>
<tr>
<td class="label">Histamine N-methyltransferase (HNMT)</td>
<td>Degrades histamine in CNS</td>
</tr>
<tr>
<td class="label">H1R, H2R, H3R, H4R</td>
<td>Histamine receptors</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">H3R antagonist</td>
<td>Pitolisant</td>
</tr>
<tr>
<td class="label">H3R antagonist</td>
<td>Cilf</td>
</tr>
<tr>
<td class="label">H1R agonist</td>
<td>Betahistine</td>
</tr>
</table>
The tuberomammillary nucleus (TMN) of the posterior hypothalamus is the sole source of histamine in the central nervous system. Histaminergic [neurons](/entities/neurons) in the TMN project broadly throughout the brain, regulating wakefulness, arousal, attention, memory consolidation, and energy homeostasis. These neurons play critical roles in neurodegenerative diseases, particularly [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), where progressive loss of histaminergic signaling contributes to disease symptomatology and progression. [@haas2020]
The tuberomammillary nucleus is located in the ventral posterior hypothalamus, adjacent to the mammillary bodies. It consists of approximately 64,000 neurons in the adult human brain, making it one of the smallest nuclei in the hypothalamus. [@panula2020] Despite its small size, the TMN has remarkably widespread projections to nearly every region of the forebrain and brainstem.
TMN neurons receive input from:
Histaminergic axons project to:
The enzyme [HDC](/genes/hdc) (histidine decarboxylase) is the exclusive source of neuronal histamine. Genetic variants in HDC have been linked to neuropsychiatric disorders, and HDC expression decreases with aging and neurodegeneration. [@kubota2020]
Histamine is a key wakefulness-promoting neurotransmitter. TMN neurons are active during wake, reduce firing during NREM sleep, and are silent during REM sleep. This activity pattern is opposite to that of [orexin neurons](/cell-types/orexin-neurons), and the two systems work synergistically to maintain arousal.
Histamine regulates feeding behavior through H1R signaling in the hypothalamus. TMN neurons integrate metabolic signals (leptin, ghrelin) to modulate appetite and energy expenditure.
Histamine exhibits anti-inflammatory properties through H4R signaling on immune cells. It can modulate [microglial activation](/cell-types/microglia) and reduce excitotoxicity through H2R-mediated mechanisms. [@fellner2021]
In [Alzheimer's Disease](/diseases/alzheimers-disease), the TMN undergoes significant degeneration, with loss of up to 40% of histaminergic neurons by Braak stage III-IV. This loss correlates with cognitive decline and sleep disturbances. [@shan2020]
The tuberomammillary nucleus is affected in [Parkinson's Disease](/diseases/parkinsons-disease) by [alpha-synuclein](/proteins/alpha-synuclein) pathology, with Lewy bodies found in histaminergic neurons. This involvement contributes to the non-motor symptoms of PD. [@juri2020]
Histaminergic deficits in PD contribute to:
Histamine modulates [microglial activation](/cell-types/microglia-neurodegeneration-alzheimer) through H4R signaling. Loss of histaminergic anti-inflammatory effects may contribute to chronic neuroinflammation in both AD and PD.
TMN dysfunction affects hypothalamic energy regulation, potentially linking neurodegeneration to metabolic disturbances common in AD and PD patients.
The tuberomammillary nucleus and its histaminergic neurons represent a critical yet underappreciated component of neurodegenerative disease pathophysiology. The loss of histaminergic signaling contributes to sleep-wake disturbances, cognitive impairment, and neuroinflammation in both Alzheimer's and Parkinson's diseases. Therapeutic targeting of the histamine system offers a promising avenue for addressing non-motor symptoms and potentially modifying disease progression.